Pulmoner hipertansiyon tanı ve tedavisi

GÖK, HASAN; AKILLI, Hakan; Yildirim, Oguzhan

Pulmoner hipertansiyon tanı ve tedavisi

Oğuzhan YILDIRIM, (Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Konya, Türkiye)

Hakan AKILLI, (Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Konya, Türkiye)

Hasan GÖK (Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Konya, Türkiye)

MN Kardiyoloji

6 1

Yıl: 2013 Cilt: 20 Sayı: 1 Sayfa Aralığı: 41 - 48 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Pulmoner hipertansiyon tanı ve tedavisi

Öz:

Pulmoner hipertansiyonun (PH) etyolojik olarak birçok sebebi mevcut olup, sebebi ne olursa olsun ilerleyici ve sinsi bir hastalıktır. PH’nın kendine özgü semptomlarının olmamasından dolayı tanı konulması gecikmekte ve ileri evrelerde tanı konmaktadır. PH ileri ev- relerde tedaviye daha az yanıt vermesi ve prognozunun kötü olması sebebiyle erken tanı ve tedavisi önem arz etmektedir Pulmoner hipertansiyon tanısı konulduktan sonraki basamak, hastanın kliniğinin ağırlık derecesinin belirlenmesidir. Dünya Sağlık Örgütü (DSÖ) FS I veya II hastalarda tedavi edilmediğinde 4 yıllık sağkalım %50’nin altındadır. DSÖ fonksiyonel sınıflar (FS) III veya IV hastalarda ise 2 yıllık sağkalım %60’ın altındadır. Hafif semptomatik hastalarda bile, PH tedavi edilmediğinde hızla kötüleşmektedir. Pulmoner hipertansiyon tedavisinde amaç; PH şiddetini azaltmak, fonksiyonel kapasitesini, yaşam kalitesini düzeltmek, sağ ventrikül işlevlerini iyileştirmek, oluşabilecek tromboembolik yükü azaltmak ve iyi prognoz sağlamaktır. Bu yazıda güncel kılavuzlar ışığında pulmoner hipertansiyon tanı ve tedavisi anlatılmıştır.

Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi

Pulmonary hypertension diagnosis and treatment

Öz:

Pulmonary hypertension has many etiological reasons and it is a progressive and insidious disease regardless of the underlying cause. The diagnosis of PH is generally delayed to advanced stages as it does not have pathagonomic symptoms and signs. The response of PH to the treatment is less and the prognosis is poor at advanced stages so early diagnosis and treatment is important. The next step after the diagnosis of PAH is to determine the severity of the disease. 4 year survival of World Health Organization (WHO) fonksional class (FC) 1 or 2 without treatment is less than 50% 2 year survival of WHO FC 3 or 4 patient is less than 60% Patients with even minor symptoms without treatment get worsen progressively. The aim of pulmonary arterial hypertension (PAH) treatment is to decrease the severity of PAH, to increase life quality, functional capacity and right ventricul functions, and to prevent possible thromboembolic events. In this paper we discussed the diagnosis and treatment of pulmonary hypertension with current guidelines.

Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Gali N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
2. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-23
3. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Resp Crit Care Med 2009;179:615-21
4. Tunariu N, Gibbs SJR, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multide-tector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007;48:680-4
5. Dartevelle P, Fadel E, Mussot S, et al. Chronic throm- boembolic pulmonary hypertension. Eur Respir J 2004; 23:637-48.
6. Torbicki A. Cardiac magnetic resonance in pulmonary arterial hypertension: a step in the right direction. Eur Heart J 2007;28:1187-9.
7. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006;48:2546-52.
8. Sitbon O, Humbert M, Jais X, loos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111: 3105-11.
9. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidencebased treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:78
10. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pul-monary hypertension. Circulation 2006;114:1482-9.
11. Bedard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? EurHeart J 2009;30:256-65.
12. Bendayan D, Hod M, Oron G, et al. Pregnancy outcome in patients with pulmonary arterial hypertension receiving prostacyclin therapy. Obstet Gynecol 2005;106:1206-10.
13. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70:580-7
14. Kawut SM, Horn EM, Berekashvili KK, et al. New predictors of outcome in idiopathic pulmonary arterial hypertesion. Am J Cardiol 2005;95:199
15. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998;114:787-92.
16. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985;131:493-8
17. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
18. Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen activated protein kinase signaling cascades. Mol Pharmacol 1995;48:890-6
19. Galie N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2003;2:123-37
20. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
21. Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999; 34:1188-92.
22. Wharton J, Strange JW, Moller GMO, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005;172:105-113.
23. Galie N, Ghofrani HA, Torbicki A, et al. The Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. New Engl J Med 2005;353:2148-57.
24. Galie `N, Brundage B, Ghofrani A, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119:2894-903
25. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-9.
26. Galie `N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-100.
27. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective en- dothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-56
28. Gruenig E, Michelakis E, Vachiery JL,et al. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of COMPASS-1 study. J Clin Pharmacol 2009;49:1343-52.
29. Kurzyna M, Dabrowski M, Bielecki D, et al. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest 2007;131: 977-83.
30. Manes A, Marinelli A, Palazzini M, et al. Pulmonary arterial hypertension. Part 2: Medical and surgical treatment. G Ital Cardiol (Rome) 2009;10:366-381

APA	Yildirim O, AKILLI H, GÖK H (2013). Pulmoner hipertansiyon tanı ve tedavisi. , 41 - 48.
Chicago	Yildirim Oguzhan,AKILLI Hakan,GÖK HASAN Pulmoner hipertansiyon tanı ve tedavisi. (2013): 41 - 48.
MLA	Yildirim Oguzhan,AKILLI Hakan,GÖK HASAN Pulmoner hipertansiyon tanı ve tedavisi. , 2013, ss.41 - 48.
AMA	Yildirim O,AKILLI H,GÖK H Pulmoner hipertansiyon tanı ve tedavisi. . 2013; 41 - 48.
Vancouver	Yildirim O,AKILLI H,GÖK H Pulmoner hipertansiyon tanı ve tedavisi. . 2013; 41 - 48.
IEEE	Yildirim O,AKILLI H,GÖK H "Pulmoner hipertansiyon tanı ve tedavisi." , ss.41 - 48, 2013.
ISNAD	Yildirim, Oguzhan vd. "Pulmoner hipertansiyon tanı ve tedavisi". (2013), 41-48.

APA	Yildirim O, AKILLI H, GÖK H (2013). Pulmoner hipertansiyon tanı ve tedavisi. MN Kardiyoloji, 20(1), 41 - 48.
Chicago	Yildirim Oguzhan,AKILLI Hakan,GÖK HASAN Pulmoner hipertansiyon tanı ve tedavisi. MN Kardiyoloji 20, no.1 (2013): 41 - 48.
MLA	Yildirim Oguzhan,AKILLI Hakan,GÖK HASAN Pulmoner hipertansiyon tanı ve tedavisi. MN Kardiyoloji, vol.20, no.1, 2013, ss.41 - 48.
AMA	Yildirim O,AKILLI H,GÖK H Pulmoner hipertansiyon tanı ve tedavisi. MN Kardiyoloji. 2013; 20(1): 41 - 48.
Vancouver	Yildirim O,AKILLI H,GÖK H Pulmoner hipertansiyon tanı ve tedavisi. MN Kardiyoloji. 2013; 20(1): 41 - 48.
IEEE	Yildirim O,AKILLI H,GÖK H "Pulmoner hipertansiyon tanı ve tedavisi." MN Kardiyoloji, 20, ss.41 - 48, 2013.
ISNAD	Yildirim, Oguzhan vd. "Pulmoner hipertansiyon tanı ve tedavisi". MN Kardiyoloji 20/1 (2013), 41-48.